During a Case-Based Roundtable® event, Robert Z. Orlowski, MD, PhD, discussed the case of a patient who had progression of ...

We believe Genmab is in solid financial health. At the end of 2024, Genmab held DKK 9.9 billion in cash and cash equivalents. After turning profitable in 2013, the company has steadily increased its ...

The results of this report were complemented by another similar initiative, the meta-analysis Evaluate Minimal Residual Disease as an Intermediate Clinical Endpoint for Multiple Myeloma (EVIDENCE ...

Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...

Multiple myeloma (MM), which is caused by the transformation ... diagnosed with MM in combination with melphalan (Alkeran; Celgene) and prednisone. This combination, also known as VMP, produced ...

NHS patients in England with newly-diagnosed multiple myeloma can be treated with Celgene’s Revlimid as maintenance therapy after a stem cell transplant, after new guidance from NICE.

S Lional is supported by the Richard and Annelly Deets Fund for Multiple Myeloma and acts as a consultant for Millennium, Celgene, Novartis, Onyx, BMS, Merck and Acetylon. The authors have no ...

Lenalidomide (Revlimid; Celgene) was initially approved in the US in 2005, and has since been approved for the treatment of patients with multiple myeloma, anemia due to MDS, relapsed or ...

Sanofi has claimed FDA approval for its anti-CD38 drug isatuximab as a third-line treatment for multiple myeloma, becoming the first direct rival to Johnson & Johnson’s big-selling Darzalex.

KSQ Therapeutics, Inc. (KSQ), a clinical-stage biotechnology company developing novel treatments for solid tumors, including ...